SCHEMBL26095023

SCHEMBL26095023

Cc1c[c]ccc1Oc1ccc(N)cn1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.56
KDM4E B2RXH2 5/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
POLB P06746 2/20 0.47
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.42
BRCA1 P38398 1/20 0.42
HBB P68871 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX5AP P20292 2/20 0.36
FEN1 P39748 2/20 0.36
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAP4K4 O95819 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5171558 0.82 KMT2A (0.63) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL12593846 0.78 KEAP1 (0.62) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL4064464 0.78 KEAP1 (0.77) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL4712158 0.76 HSPB1 (0.51) KDM4EMEN1KMT2ARAB9AALDH1A1
SCHEMBL4065605 0.75 KEAP1 (0.59) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL4717640 0.74 KDM4E (0.64) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL4070182 0.73 KEAP1 (0.60) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL4061973 0.73 KDM4E (0.60) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL12594180 0.72 KEAP1 (0.52) KEAP1KDM4EMEN1KMT2APOLB
SCHEMBL1014038 0.72 KEAP1 (1.00) KEAP1KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, IDH2, MDH2 KEAP1 442/4885KDM4E 446/4885MEN1 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.